Metastatic Breast Cancer: Subgroup Analyses of the German non-Intervention Study

被引：0
作者：
不详
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2013年 / 51卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A7 / A7
页数：1
相关论文
共 4 条
  • [1] Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer
    Gray, Robert
    Bhattacharya, Suman
    Bowden, Christopher
    Miller, Kathy
    Comis, Robert L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) : 4966 - 4972
  • [2] Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
    Miles, David W.
    Chan, Arlene
    Dirix, Luc Y.
    Cortes, Javier
    Pivot, Xavier
    Tomczak, Piotr
    Delozier, Thierry
    Sohn, Joo Hyuk
    Provencher, Louise
    Puglisi, Fabio
    Harbeck, Nadia
    Steger, Guenther G.
    Schneeweiss, Andreas
    Wardley, Andrew M.
    Chlistalla, Andreas
    Romieu, Gilles
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3239 - 3247
  • [3] RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
    Robert, Nicholas J.
    Dieras, Veronique
    Glaspy, John
    Brufsky, Adam M.
    Bondarenko, Igor
    Lipatov, Oleg N.
    Perez, Edith A.
    Yardley, Denise A.
    Chan, Stephen Y. T.
    Zhou, Xian
    Phan, See-Chun
    O'Shaughnessy, Joyce
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (10) : 1252 - 1260
  • [4] Schrader I, ASCO 2012
1